In the setting of the current COVID19 pandemic, there has been urgency to develop potent antiviral treatments, and early efforts have hearkened back to the days of von Behring, who won the Nobel prize for showing that antibodies can be transferred in serum. However, technology advances over the last century have allowed for the progression from convalescent serum to the utilization of recombinant fully human antibodies. The proposal to genetically humanize the immune system of mice ([@R1]) provided an efficient source of naturally-selected fully-human antibodies. For example, such mice were used to develop checkpoint inhibitors for immune- oncology ([@R2]), as well as FDA-approved antibodies for the treatment of rheumatoid arthritis, cardiovascular disease, cutaneous squamous cell carcinoma, and allergic diseases such as asthma and atopic dermatitis. More recently, the ability to sort individual B cells from previously infected human patients -- and molecularly clone the antibody genes from these B cells -- has led to an independent source of human antibodies, albeit limited to antibodies targeting infectious agents. Recently, these two fundamentally different approaches were independently exploited to develop fully-human antibody treatments for the lethal infectious disease caused by the Ebola virus: genetically humanized "*VelocImmune®*" (VI) mice ([@R3], [@R4]) generated an Ebola antibody cocktail treatment ([@R5]), while sorting of B cells from a recovered patient yielded a single therapeutic antibody treatment ([@R6]).

Here we describe parallel high-throughput efforts using both mice and humans to generate antibodies against the spike protein of SARS-CoV-2. The ability to derive antibodies using genetically humanized VI mice as well as B cells derived from convalescent patients enabled us to isolate a very large collection of fully human antibodies with diverse sequences, binding properties, and antiviral activity. The prospective goal of these parallel efforts was to generate a large and diverse collection so as to allow for the selection of pairs of highly potent individual antibodies that could simultaneously bind the critical Receptor Binding Domain (RBD) of the spike protein, providing ideal partners for a therapeutic antibody cocktail that would have the potential to decrease the likelihood of virus escape mutants that might arise in response to selective pressure from single antibody treatments ([@R7]).

Anti-SARS-CoV-2 spike antibodies were generated with the following two methods. First, by immunizing VI mice with a DNA plasmid that expresses SARS-CoV-2 spike protein and then boosting with recombinant protein comprised of the RBD of SARS-CoV-2 spike. Second, by isolation from PBMCs of human donors previously infected with SARS-CoV-2. VI mice elicited a robust immune response against the SARS-CoV-2 spike protein post-immunization. Titers of the bleeds of the mice collected 7 days after the last boost were determined by ELISA (fig. S1). Mice with the highest titers were used for antibody isolation. Spleens from these mice were subjected to biotin-labeled monomeric RBD antigen staining, and FACS single cell sorting. In parallel, whole blood was received from 3 patients 3-4 weeks post laboratory-confirmed PCR positive test for SARS-CoV-2 and symptomatic COVID-19 disease; PBMCs were isolated by ficoll gradient and RBD-specific B cells were FACS single cell sorted. The first sets of antibodies derived from these platforms are described herein.

To assess antigen specific responses, naturally-paired heavy and light chain cDNAs were cloned from the mouse and human derived B cells ([@R8]) and transfected into Chinese hamster ovary (CHO) cells to produce recombinant fully-human antibodies. Cultured supernatants containing secreted antibodies were subjected to high-throughput screening for RBD protein binding. Thousands of antibodies were isolated and subsequently screened for binding affinity to RBD monomer and dimer, epitope diversity, ability to block ACE2 receptor binding to RBD, and neutralize VSV-based SARS-CoV-2 spike pseudoparticles (pVSV-SARS-CoV-2-S(mNeon)). Screening yielded over 200 neutralizing mAbs with broad potency ranges, dozens of which displayed neutralization potency in the pM range.

Over 200 of the VI and human derived antibodies isolated in the primary screen neutralized VSV-based SARS-CoV-2 Spike pseudoparticles at \>70% with \~2μg/ml of expressed antibodies. The antibody variable regions were sequenced by Next Generation Sequencing and the repertoire for heavy and light chain pairs was identified ([Fig. 1](#F1){ref-type="fig"}). The predominant lineage of VI antibodies utilized VH3-53 paired with VK1-9, VK1-33, or VK1-39, while our human-derived antibodies utilized VH3-66 paired with VK1-33 or VH2-70 paired with VK1-39. Interestingly, VH3-53 usage has recently been reported for another human-derived potent neutralizing antibody against SARS-CoV-2 spike protein ([@R9]--[@R11]), indicating that combining the VI mouse approach with the human platforms allows expanded capture of common rearrangements found in potent neutralizing SARS-CoV-2 mAbs seen in humans. Further analysis of overlaid sequences (fig. S2.) showed strong overlap in the repertoire of isolated kappa chains between VI and human-derived antibodies. Although the repertoire of Lambda chains did not overlap well that may be due to only two lambda mice being included in this trial. The average CDR length (fig. S2D) for heavy chain was similar between VI and human derived antibodies with an average length of 13 and 14.5 amino acids, respectively. Average kappa CDR length (fig. S2E) was the same for VI and human derived antibodies at 9 amino acids and was close for lambda chains (fig. S2F) with an average length of 11.1 and 10.6 amino acids, respectively.

![Paired antibody repertoire for human and mouse-derived SARS-CoV-2 neutralizing antibodies.\
(**A** and **B**) V gene frequencies for paired Heavy (X-axis) and Light (Y-axis) chains of isolated neutralizing antibodies to SARS-CoV-2 for VelocImmune® mice (Left panel; N=185) and convalescent human donors (Right panel; N=68). The color and size of the circle corresponds to the number of Heavy and Light chain pairs present in the repertoires of isolated neutralizing antibodies. Neutralization is defined as \>70% with 1:4 dilution of antibody (\~2ug/ml) in VSV pseudoparticle neutralization assay.](abd0827-F1){#F1}

Approximately 40 antibodies with unique sequences and potent neutralization activity were chosen for additional characterization as described below. The neutralization potency of these mAbs spanned the single digit to triple digit pM range in the VSV-based pseudoparticle assay. While we did identify antibodies that bound to the SARS-CoV-1 spike protein (data not shown), these were weakly neutralizing, supporting previously published reports describing SARS-CoV-1 and SARS-CoV-2 cross-neutralizers ([@R12]). Instead we further focused on nine of the most potent neutralizing mAbs, with neutralization potencies ranging from 7 pM to 99 pM ([Fig. 2A](#F2){ref-type="fig"} and table S1). All of these neutralizing mAbs bound to the RBD of SARS-CoV-2 spike and blocked its ability to interact with ACE2 with double-digit pM IC50s (table S1), supporting ACE2 blockade as the primary mechanism for neutralization. The antibodies bound specifically and with high affinity to monomeric SARS-COV-2 RBD (KD = 0.56 to 45.2nM) and dimeric SARS-COV-2 RBD (KD = 5.7 to 42.8 pM). As recombinant ACE2 receptor is being considered as a COVID19 therapeutic ([@R13]), we tested the potency of recombinant dimeric human ACE2-Fc (hACE2-hFc) in our neutralization assay. While recombinant ACE2 was able to mediate neutralization of the VSV-spike pseudoparticles as previously reported, it was more than 1000-fold less potent than the best neutralizing mAbs ([Fig. 2, A and B](#F2){ref-type="fig"}).

![Neutralization potency of anti-SARS-CoV-2 spike mAbs.\
(**A**) Serial dilutions of anti-spike mAbs, IgG1 isotype control, and recombinant dimeric ACE2 (hACE2.hFc) were added with pVSV-SARS-CoV-2-S-mNeon to Vero cells and mNeon expression was measured 24 hours post-infection as a read-out for virus infectivity. Data are graphed as percent neutralization relative to virus only infection control. (**B**) Neutralization potency of anti-spike mAbs, recombinant dimeric ACE2, and IgG1 isotype control against non-replicating pVSV-SARS-CoV-2-S-mNeon in Calu3 cells. (**C**) Neutralization potency of individual anti-spike mAbs and combinations of mAbs against replicating VSV-SARS-CoV-2-S virus in Vero cells. Cells were infected with an MOI 1 of the virus and stained for viral protein 24 hours post-infection to measure infectivity. (**D**) Neutralization potency of individual anti-spike mAbs and combinations of mAbs against SARS-CoV-2-S virus in VeroE6 cells.](abd0827-F2){#F2}

A smaller collection of four antibodies was chosen for further analyses to determine whether the above binding data to RBD reflected binding to trimeric spike protein, whether neutralization potencies noted in the above assays were consistent with those seen in other assays including with SARS-CoV-2, and whether these antibodies retained neutralization activity against pseudoparticles with mutations in the S1/S2 cleavage site. Binding affinity of these four antibodies against trimeric SARS-CoV-2 spike (KD = 37.1 to 42.8 pM) largely paralleled the affinity against the RBD (table S3). In addition, the potent neutralizing activity of these four antibodies was confirmed in the additional neutralization assays, including pVSV-SARS-CoV-2-S(mNeon) neutralization in the human lung epithelial Calu3 cell line, neutralization of replicating VSV-SARS-CoV-2-S in Vero cells, and neutralization of SARS-CoV-2 in VeroE6 cells ([Fig. 2, B to D](#F2){ref-type="fig"}). All neutralization assays generated similar potency across the four mAbs and no combinations demonstrated synergistic neutralization activity ([Fig. 2, C and D](#F2){ref-type="fig"}). As previous reports indicate pseudoparticles containing the SARS-CoV-2 Spike are pre-cleaved by furin-like proteases at the polybasic S1/S2 cleavage site during biogenesis in HEK293T cells, we assessed the impact of this cleavage on mAb neutralization potency. Spike stabilized pseudoparticles (fig. S3A) with a monobasic cleavage site (FurMut) in the S1/S2 interface or deleted region (FurKO) were produced as previously described ([@R14], [@R15]). No differences were observed in neutralization of either FurMut or FurKO containing pseudoparticles relative to wild-type (WT) in Vero cells (fig. S3B). Interestingly, stabilized pseudoparticles had comparable or greater infectivity to those with WT cleavage sites in Vero cells, whereas dramatic loss of infectivity was observed in Calu-3 cells (fig. S3C). Authentic SARS-CoV-2 with a natural deletion of the S1/S2 junction also had defects in infectivity in Calu-3, but not in Vero cells ([@R16]), implicating differential protease usage between these two cell types. To investigate the mechanism of neutralization we generated Fab fragments for the four antibodies. We compared IgG to corresponding Fabs side-by-side for their ability to neutralize pseudotyped VSV (fig. S4). The IC50s of all the Fabs was shifted compared to their parental IgG, indicating that bivalent binding, cross-linking and steric hindrance might all augment neutralization.

Although the role of antibody effector function in protection against SARS-CoV-2 is yet unknown, it is well established to play an important role in mAb therapeutic efficacy against other viruses such as Ebola and influenza viruses ([@R17]--[@R19]). Effector cells including macrophages and monocytes were also shown to be important for antibody mediated protection from SARS-CoV-1 infection ([@R20]). To understand whether our lead antibodies are capable of mediating effector function, we assessed both Antibody Dependent Cellular Cytotoxicity (ADCC) and Antibody Dependent Cellular Phagocytosis (ADCP) activity in primary human cell bioassays utilizing NK cells and monocyte derived phagocytes. All four lead antibodies demonstrated the ability to mediate ADCC and ADCP, albeit to slightly different degrees. REGN10987 displayed superior ability to mediate ADCC relative to the other three mAbs, while it performed similarly to REGN10989 and REGN10933 in the ADCP assay (fig. S5 and table S3). Although REGN10934 was able to mediate both ADCC and ADCP, it was not as strong of an inducer in those assays as the other three mAbs (fig. S6 and table S4). Further identification of mAb epitopes through high resolution structural analysis may help illuminate the relationship between specific epitopes and effector function of anti-spike mAbs.

A prospective goal of our effort was to identify highly potent individual antibodies that could be paired in a therapeutic antibody cocktail, aiming to decrease the potential for decreased efficacy due to variants arising as the pandemic spreads, as well as due to virus escape mutants that might be selected in response to pressure from a single antibody treatment ([@R7]). We thus examined our nine most potent neutralizing antibodies in cross-competition binding assays (fig. S7), identifying several pairs of non-competing mAbs with pM neutralization potency that could potentially be combined to form antibody cocktails. To further study the binding regions of our mAbs on spike protein RBD, we performed Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) with the same nine antibodies ([Fig. 3](#F3){ref-type="fig"}), revealing where each of the antibodies contacts the surface of the RBD, and allowing comparison with the ACE2 binding site on the RBD ([Fig. 3](#F3){ref-type="fig"}). As might be expected, most of our neutralizing antibodies contact the RBD in a manner that overlaps the RBD residues that comprise the ACE2 interface; furthermore, the antibodies can be grouped based on their pattern of contacting the RBD surface. Comparing the cross-competition binding assays with the HDX-MS results provides structural insights into the mechanism by which non-competing pairs of antibodies can simultaneously bind the RBD, and can thus be ideal partners for a therapeutic antibody cocktail. REGN10987 and REGN10933 represent such a pair of antibodies: REGN10933 targets the spike-like loop region on one edge of the ACE2 interface. Within that region, the residues that show the most significant HDX protection by REGN10933 face upward, suggesting that the Fab region of REGN10933 binds the RBD from the top direction, where REGN10933 will have significant collisions with ACE2. In order to avoid competition with REGN10933, REGN10987 can only bind to the HDX defined protected regions from the front or the lower left side (in the front view of REGN10987 in [Fig. 3](#F3){ref-type="fig"}). This would be consistent with the neutralization data, as REGN10987 would orient itself in a position that has high probability to interfere with ACE2. Confirming the above data, single-particle cryoEM of the complex of SARS-CoV-2 spike RBD bound to Fab fragments of REGN10933 and REGN10987 shows that the two antibodies in this cocktail can simultaneously bind to distinct regions of the RBD ([Fig. 4](#F4){ref-type="fig"} and table S5). A 3D reconstructed map of the complex with nominal resolution of 3.9Å shows that the two Fab fragments bind at different epitopes on the RBD confirming that they are non-competing antibodies. REGN10933 binds at the top of the RBD, extensively overlapping the binding site for ACE2. On the other hand, the epitope for REGN10987 is located on the side of the RBD, away from the REGN10933 epitope, and has little to no overlap with the ACE2 binding site.

![Hydrogen-Deuterium Exchange Mass Spectrometry determines mAb interaction on Spike protein RBD.\
3D surface model for the structure of the Spike protein RBD domain showing the ACE2 interface and HDX-MS epitope mapping results. RBD residues that make contacts with ACE2 ([@R21], [@R22]) are indicated in yellow (top panel). RBD residues protected by anti-SARS-CoV2-Spike antibodies are indicated with colors that represent the extent of protection as determined by HDX-MS experiments. RBD residues in purple and blue indicate sites of lessor solvent exchange upon antibody binding and have greater likelihood to be antibody binding residues. The RBD structure is reproduced from PDB 6M17 ([@R21]).](abd0827-F3){#F3}

![Complex of REGN10933 and REGN10987 with the SARS-CoV-2 RBD.\
(**A**) 3.9 Å cryoEM map of REGN10933 + RBD + REGN10987 complex, colored according to the chains in the refined model (**B**). RBD is colored dark blue, REGN10933 heavy and light chains are green and cyan, and REGN10987 heavy and light chains are yellow and red, respectively.](abd0827-F4){#F4}

We report remarkable similarities and consistencies in the antibodies generated from genetically-humanized mice and from convalescent humans. The scale of the genetic-engineering approach used to create the VI mouse (involving genetic-humanization of over 6 mega-bases of mouse immune genes) has resulted in the ability to effectively and indistinguishably mimic the antibody responses of normal humans. The genetically-humanized mouse approach has the advantage that it can potentially allow for further immunization optimization strategies, and also that it can be applied to non-infectious disease targets. By combining the efforts from two parallel and high-throughput approaches for generating antibodies to the RBD of the SARS-CoV-2 spike protein, we generated a sufficiently large collection of potent and diverse antibodies that we could meet our prospective goal of identifying highly potent individual antibodies that could be combined into a therapeutic antibody cocktail. Inclusion of such antibodies into an antibody cocktail may deliver optimal antiviral potency while minimizing odds of virus escape ([@R7]), two critical desired features of an antibody-based therapeutic for treatment and prevention of COVID19. Such an antibody cocktail is now being tested in human trials (clinicaltrials.gov NCT04426695 and NCT04425629).
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